HOME >> MEDICINE >> NEWS
CRESTOR leads in 1st international prospective study of statins in the metabolic syndrome

Index (Global and European) as well as the FTSE4Good Index. AstraZeneca has more than 40 years experience in cardiovascular medicine and aims to increase lifespan and improve quality of life by reducing the risk, prevalence and impact of cardiovascular disease. AstraZeneca has a comprehensive cardiovascular portfolio including CRESTORTM, ATACANDTM, ZESTRILTM, TENORMINTM, SELOKEN ZOK /TOPROL-XLTM and PLENDILTM. This heritage is complemented by an innovative pipeline including the first oral direct thrombin inhibitor, EXANTATM, and a novel treatment for type 2 diabetes / metabolic syndrome, GALIDATM.


'"/>

Contact: Rachael Wood
rachael.wood@astrazeneca.com
44-162-551-9514
Shire Health International
6-Sep-2004


Page: 1 2 3 4

Related medicine news :

1. 1st data show CRESTOR highly effective at lowering LDL-C in patients with type 2 diabetes
2. CRESTOR (TM) improves apolipoprotein and lipid ratios - markers of cardiovascular disease risk
3. Corrected metabolism leads to health benefits and weight loss
4. Combining PET and CT scans leads to more accurate radiation therapy for lung cancer patients
5. Lack of specific collagen type leads to osteoarthritis
6. UCI study uncovers how plaque in neck artery leads to stroke-inducing blood clots
7. Vaginal hysterectomy leads to better outcomes than abdominal surgery
8. Little evidence that breast cancer diagnosis leads to employment discrimination, study concludes
9. Marine sponge leads researchers to immune system regulator
10. Safer drug prescribing for seniors in nursing homes: Canada leads the way
11. Malnutrition in early years leads to low IQ and later antisocial behavior, USC study finds

Post Your Comments:
(Date:9/4/2015)... ... , ... Mike Day, a former Navy SEAL who was shot 27 times ... in Kona on October 10th. , Mike is running the race to raise awareness ... the cutting-edge treatments that restore their quality of life. More than 300,000 ...
(Date:9/4/2015)... , ... September 04, 2015 , ... Having access to ... has led to an increasing amount of unnecessary emergency room visits which affects hospitals’ ... taxes the country’s health bill. Fortunately, a solution to alleviate this problem has recently ...
(Date:9/4/2015)... , ... September 04, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... are prophetic details involving the Pope’s upcoming trip to the United States. , Yisrayl lays ... his role with the Vatican and society is. Yisrayl also provides the meaning of his ...
(Date:9/3/2015)... ... ... While bariatric surgeon Michael Feiz, M.D., F.A.C.S. notes that he advises all ... some patients have been recently asking further questions relating to the best way to ... surgery that should be followed in the days prior to the procedure, Dr. Feiz ...
(Date:9/3/2015)... ... 03, 2015 , ... The Oregon Collaborative for Integrative Medicine ... & Medicine (AIHM) Interprofessional Fellowship in Integrative Health & Medicine. The AIHM Fellowship ... renowned educator, physician and thought leader in integrative medicine. This is the first ...
Breaking Medicine News(10 mins):Health News:Navy SEAL Shot 27 Times Competes in Ironman World Championship in Kona to Raise Money for Veteran's Suffering from TBI and PTSD 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 3Health News:Yisrayl Hawkins Writes Open Letter to Pope Francis In Light of Approaching U.S. Visit 2Health News:Dr. Feiz and Associates Answer August's ‘Patient Submitted Question of the Month’: “How Can I Prepare for Weight Loss Surgery” 2Health News:Oregon Collaborative for Integrative Medicine Partners with AIHM on First Interprofessional Fellowship 2Health News:Oregon Collaborative for Integrative Medicine Partners with AIHM on First Interprofessional Fellowship 3
(Date:9/4/2015)... LONDON , September 4, 2015 ... & Vaccines  Allergic Rhinitis drugs ... revenues Where is the market for allergic ... this market? Visiongain ,s new report shows you ... opportunities and prospects. Our 326 page report ...
(Date:9/4/2015)... Sep. 04, 2015 Research and ... "Investigation Report on China,s Sodium Ibandronate Market, 2010-2019" ... in the clinic under the trade name of Bondronat in ... in 1996, sodium ibandronate was approved by the FDA ... osteoporosis under the trade name of Boniva. However, since drug ...
(Date:9/4/2015)... , September 4, 2015 ... today announces that Hutchison MediPharma Limited ("HMP"), its ... in the second proof-of-concept ("POC") trial of fruquintinib ... cancer ("NSCLC") in China . ... succeeded in meeting the primary efficacy endpoint of ...
Breaking Medicine Technology:Allergic Rhinitis Drugs Market Forecast 2015-2025 2Allergic Rhinitis Drugs Market Forecast 2015-2025 3Allergic Rhinitis Drugs Market Forecast 2015-2025 4Allergic Rhinitis Drugs Market Forecast 2015-2025 5Allergic Rhinitis Drugs Market Forecast 2015-2025 6Allergic Rhinitis Drugs Market Forecast 2015-2025 7Investigation Report on China's Sodium Ibandronate Market 2010-2019 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 3
Cached News: